Linked Life Data

1375533

Source:http://linkedlifedata.com/resource/pubmed/id/1375533

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
1992-6-30
pubmed:abstractText
Macrophage colony-stimulating factor (CSF-1) increases the tissue invasive potential of the CSF-1 receptor-bearing lung carcinoma cell lines A549 and Calu-1 by increasing the number of endogenously bound urokinase-type plasminogen activators (u-PA)s on these cells. CSF-1, at concentrations which optimize invasion of A549 and Calu-1 cells into human amnion membranes (250 ng/ml), maximally augments the number of u-PA receptors occupied by endogenously produced urokinase. Preincubation of A549 and Calu-1 cells with the anti-u-PA monoclonal antibody MPW5UK (25 micrograms/ml) or with a 20- to 40-fold stoichiometric excess of fluid phase type 2 plasminogen activator inhibitor abrogates invasiveness, indicating that functionally active cell surface u-PA is essential for tissue invasion. In contrast, fluid phase type 1 plasminogen activator inhibitor (PAI-1, 5-15 units/ml) does not inhibit invasiveness unless preincubated with the amnion membranes. Inhibition of invasion by PAI-1 is abolished by presaturating the amnion membranes with antiitronectin monoclonal antibody (10 micrograms/ml) which prevents binding of PAI-1 to tissue-associated vitronectin. Binding of PAI-1 to tissue vitronectin is therefore a prerequisite for its inhibitory action. Thus, endogenously receptor-bound u-PA is the primary protease mediating CSF-1-induced tissue invasiveness of the lung carcinoma cell lines A549 and Calu-1.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0008-5472
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
52
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3043-7
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:1375533-Amnion, pubmed-meshheading:1375533-Antibodies, Monoclonal, pubmed-meshheading:1375533-Cell Line, pubmed-meshheading:1375533-Extracellular Matrix, pubmed-meshheading:1375533-Female, pubmed-meshheading:1375533-Glycoproteins, pubmed-meshheading:1375533-Humans, pubmed-meshheading:1375533-Kinetics, pubmed-meshheading:1375533-Lung Neoplasms, pubmed-meshheading:1375533-Macrophage Colony-Stimulating Factor, pubmed-meshheading:1375533-Neoplasm Invasiveness, pubmed-meshheading:1375533-Plasminogen Inactivators, pubmed-meshheading:1375533-Pregnancy, pubmed-meshheading:1375533-Receptors, Cell Surface, pubmed-meshheading:1375533-Receptors, Urokinase Plasminogen Activator, pubmed-meshheading:1375533-Up-Regulation, pubmed-meshheading:1375533-Urokinase-Type Plasminogen Activator, pubmed-meshheading:1375533-Vitronectin
pubmed:year
1992
pubmed:articleTitle
Endogenous receptor-bound urokinase mediates tissue invasion of the human lung carcinoma cell lines A549 and Calu-1.
pubmed:affiliation
Department of Rheumatology and Immunology, Brigham and Women's Hospital, Boston, Massachusetts 02115.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't